Article

Gene fusions suggest molecular basis of prostate cancer

Recent research suggests that the common fusion of two genes may point to a molecular basis for prostate cancer.

Related Videos
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Study findings highlight gender gaps in oncology authorship and citation
NMIBC Treatment Decisions in the Age of BCG Shortages
NMIBC Treatment Decisions in the Age of BCG Shortages
Current Standards of Care and Shifting Strategies in NMIBC
Current Standards of Care and Shifting Strategies in NMIBC
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
1 expert is featured in this series.
Targeted Therapy in mHSPC: Effects of Mutation Absence
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
1 expert is featured in this series.
Treatment Strategies for Symptomatic Bone Metastases in mHSPC
Related Content
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
May 30th 2025

PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology

Benjamin P. Saylor
The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
ORIC-944 shows promise in combination with AR inhibitors in mCRPC
May 30th 2025

ORIC-944 shows promise in combination with AR inhibitors in mCRPC

Hannah Clarke
Overall, 59% of patients achieved at least a 50% decline in PSA level.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
May 29th 2025

FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer

Hannah Clarke
The company plans to submit a Biologics License Application to the FDA at the end of 2026.
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
May 29th 2025

Intraprostatic drug elution therapy shows promise for BPH-related LUTS

Hannah Clarke
Further follow-up and additional treatments in the study are ongoing.
© 2025 MJH Life Sciences

All rights reserved.